Company intelligence / Profile preview
Biolojic Design
Rehovot, Israelbiolojic.com ↗
- Ownership
- Private
- Employees
- ~77
- Development stage
- Other
01
Overview
The company's lead candidate, AU-007, is a computationally designed human IgG1 monoclonal antibody that selectively binds to the CD25-binding portion of IL-2. It was the first AI-designed antibody to enter clinical trials and is now in Phase 2 clinical trials[8][9].
- Therapeutic areas
- OncologyImmunologyEndocrinologyPulmonology
- Modalities
- AntibodiesMulti-specific antibodiesAntibody-drug conjugates (ADCs)
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
Merck KGaA (Darmstadt, Germany)Eli LillyNektar TherapeuticsTevaJohnson & Johnson Innovation (JLABS)Aulos Bioscience (spin-out with Apple Tree Partners)
Beyond the preview
Go deeper on Biolojic Design.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Biolojic Design.